The European internal neurostimulation devices market is mainly
driven by rapidly aging population and associated diseases like Alzheimer’s,
epilepsy, spinal cord injury, and Parkinson’s disease. The European internal
neurostimulation market was $947.8 million in 2013, and is expected to reach
$1715.8 million by 2018 at a CAGR of 13.0%. The internal neuromodulation market
was the largest segment constituting 87% of the overall neurostimulation market.
The report ‘The European Neurostimulation
Devices Market forecast, 2012-2018’ analyzes internal neurostimulation
market segmented by modalities including spinal cord stimulation (SCS), deep
brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation
(SNS), and gastric electrical stimulation (GES), and by applications such as
chronic pain, failed back surgery syndrome, refractory angina pectoris,
peripheral neuropathy, Alzheimer’s, Dystonia, Tourette’s Syndrome, Parkinson’s,
epilepsy, fecal incontinence, and urine incontinence and gastroparesis.
These segments experienced a
positive growth until 2012, with an increased awareness for procedures and
sophisticated diagnostic techniques. With a market value of $2.3 and $0.6
billion, the spinal cord stimulation (SCS) and deep brain stimulation (DBS)
segments contributed 51% and 14%, in terms of value, towards the total internal
neurostimulation device market. Both the markets have been witnessing high
growth because of the increase in patient pool and procedure numbers of the
various modalities.
Procedure
volume growth is significantly higher in BIC (Brazil, India, China) and Mexico
because of fast disease progression, higher prevalence, improving healthcare
infrastructure, economic growth, broadening insurance coverage, expanding
private healthcare sector, and increasing awareness amongst people.
The prevalence of
Alzheimer’s in North America and Europe is around 5.4-6.4% in adult population
whereas in Asia, it is around 4%. The incidences of Alzheimer’s were 411,000 in
2000. This number increased to 454,000 in 2010, and is expected to reach 615,000
by 2030 and 959,000 by 2050. Such high incidence rates in neurological disorders
will positively affect the market for neuromodulation.
The report also provides an
extensive competitive landscaping of companies operating in the European
internal neurostimulation market. Major players dominating the European internal
neurostimulation market include Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.),
Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), and Neuronetics,
Inc. (U.S.) Emerging players in this market include Biocontrol Medical, ANM
Neuromodulation GmbH, and Magstim Company Limited.
Segment and country-specific
company shares, news & deals, mergers and acquisitions, segment-specific
pipeline products, product approvals, and product recalls of the major companies
have been detailed in this report.
Customization
Options
Along with the market data,
you can also customize MMM assessments that meet your company’s specific needs.
Customize to get comprehensive industry standard and deep dive analysis of the
following parameters:
Product
Analysis
Usage
pattern (in-depth trend analysis) of products (segment wise)
Product matrix which gives a detailed comparison of product
portfolio of each company mapped at country and sub-segment level
End-user adoption rate analysis of the products (segment wise
and country wise)
Comprehensive coverage of product approvals, pipeline products,
and product recalls
Epidemiology
Data
Country-specific
prevalence of Alzheimer’s ,Parkinson’s, epilepsy and stroke
Country-specific incidence of Alzheimer’s, Parkinson’s,
epilepsy, stroke
Country-specific mortality rate of stroke and epilepsy
Country-specific patient pool of Alzheimer’s, Parkinson’s,
epilepsy and stroke
Disease progression (pattern analysis)
For
more information on this report visit –
Procedure
Volume Data
Country-wise number of
surgeries for epilepsy, heart failure, Alzheimer’s, and Parkinson’s
Surgeons/Physicians
Perception analysis
Fast
turn-around analysis of surgeons’ response to market events and trends
Pattern analysis of usage of spinal cord stimulation (SCS) and
deep brain stimulation (DBS) by physicians
Surgeons’ opinion about products from different companies
Surgeons’ qualitative inputs on epidemiology data
Brand/Product
Perception Matrix
Comprehensive
study of customers perception and behavior through our inbuilt social connect
tool checking the virality and tonality of blogs
Analysis of overall brand usage and familiarity and brand
advocacy distribution (detractor/neutral/familiar)
Pricing Trends
Cost analysis of the
European internal neurostimulation devices
The European internal neurostimulation procedural investment
Competitive
Intelligence
The
company share analysis for the top players of this market in Europe
The crucial developments and strategies of the companies
inculcated in their portfolio of the European internal neurostimulation market
For More Related
Market Research Reports click here:
No comments:
Post a Comment